8-Azaprostaglandin analogs as agents for lowering intraocular pressure

Details for Australian Patent Application No. 2003231188 (hide)

Owner ALLERGAN, INC.

Inventors Dinh, Danny Thang; Burk, Robert M.; Old, David W.

Agent Davies Collison Cave

Pub. Number AU-A-2003231188

PCT Number PCT/US03/13300

PCT Pub. Number WO2003/097596

Priority 10/146,224 14.05.02 US

Filing date 28 April 2003

Wipo publication date 2 December 2003

International Classifications

C07D 207/26 Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom

A61K 031/4015 - having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide

A61P 027/06 Drugs for disorders of the senses

Event Publications

14 August 2003 Complete Application Filed

  Priority application(s): 10/146,224 14.05.02 US

29 January 2004 Application Open to Public Inspection

  Published as AU-A-2003231188

13 May 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(e). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2003231189-CHEMICAL STRUCTURAL AND COMPOSITIONAL YIELDS MODEL FOR PREDICTING HYDROCARBON THERMOLYSIS PRODUCTS

2003231187-TUMOR SUPPRESSOR GENE POLYPEPTIDES AND RELATED NUCLEIC ACIDS, HOST CELLS, COMPOSITIONS, AND METHODS OF USE IN INHIBITION OF CELL GROWTH, MODULATION OF GENE EXPRESSION, AND ENHANCEMENT OF IMMUNE-RESPONSE INDUCING EFFECT OF A VACCINE